|
 ReceptoPharm
(website)
is the Nutra Pharma holding that acts as the drug
discovery arm for the Company. ReceptoPharm is
developing proprietary therapeutic protein products
primarily for the prevention and treatment of
viral and neurological diseases in humans. The
emphasis of ReceptoPharm's approach to drug discovery
and the development of new therapeutic agents
is based upon specialized receptor-binding proteins
found in nature, especially those found in snake
venom from the cobra.
|
| RPI-MN inhibits the entry of several viruses
that are known to cause severe neurological
damage in such diseases as encephalitis and
AIDS. It is being developed first for the
treatment of HIV. |
| |
|
| RPI-78M is being developed for the treatment
of multiple sclerosis (MS). Other neurological
disorders that may be served by RPI-78M include
myasthenia gravis (MG), muscular dystrophy
(MD) and amyotrophic lateral sclerosis (ALS).
|
| |
RPI-78M and RPI-MN contain anticholinergic peptides
that recognize the same receptors as nicotine
(acetylcholine receptors) but have the opposite
effect. In a specific chemical process unique
to ReceptoPharm, the drugs are created through
a process of chemical modification and possess
several desirable properties as drugs, including:
- They lack measurable toxicity but are still
capable of attaching to and affecting the target
site on the nerve cells. This means that patients
cannot overdose.
- They display no serious adverse side effects
following years of investigations in humans
and animals.
- They are extremely stable and resistant to
heat, which gives the drugs a long shelf life.
The drugs' stability has been determined to
be over 4 years at room temperature. This is
extremely unusual for a biologic drug.
- They are easy to administer.
- RPI-78M can be administered orally-a first
for a biologic MS drug. This will present MS
patients with additional quality of life benefits
by eliminating the requirement for routine injections.
|
|
| |
|
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health– a special section of the Washington Post. |
|
|
|
|
|
|
| |
|
| Click
here to learn more about Nyloxin, our over-the-counter treatment for moderate to severe chronic pain. |
|
|
|
|
| |
|
|
| |
|
